CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

Corcept Therapeutics Announces Waiver of Condition to its Tender Offer for Common Shares

15 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Extension of Previously Announced Tender Offer

08 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 10 Million Shares of its Common Stock

08 Nov 2021 07:30:01 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Third Quarter Financial Results And Provides Corporate Update

03 Nov 2021 15:05:02 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

27 Oct 2021 15:05:01 By Nasdaq GlobeNewswire

Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer

17 Sep 2021 07:30:00 By Nasdaq GlobeNewswire

Corcept Announces Presentation of Positive Results From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients With Recurrent Platinum-Resistant Ovarian Cancer at ESMO 2021

09 Sep 2021 15:05:00 By Nasdaq GlobeNewswire

William Guyer to join Corcept as Chief Development Officer

12 Aug 2021 16:00:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

29 Jul 2021 15:05:03 By Nasdaq GlobeNewswire

Former Gilead Sciences Executive Amy E. Flood Joins Corcept Therapeutics as Chief Human Resources and Communications Officer

12 Jul 2021 07:30:00 By Nasdaq GlobeNewswire

Preliminary Results From RELIANT Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

22 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Settles Patent Litigation with Sun Pharmaceutical

15 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Appoints Joshua M. Murray to Board of Directors

10 Jun 2021 06:30:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results

06 May 2021 15:10:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH)

06 May 2021 15:05:03 By Nasdaq GlobeNewswire

Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian Cancer

06 May 2021 15:01:01 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

29 Apr 2021 15:05:01 By Nasdaq GlobeNewswire

Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess

15 Mar 2021 06:30:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Business Officer

01 Mar 2021 15:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results

23 Feb 2021 15:05:00 By Nasdaq GlobeNewswire